Part 2 of a Ten-part series: Intellectual Property as a Value Driver and Risk Factor in Life Sciences Venture Investment
Introduction
For venture capital investors in the life sciences sector, the presence of a patent portfolio is rarely sufficient to distinguish one investment target from another. Nearly every company that reaches an institutional financing round will have filed applications, and many will have issued patents to point to in a pitch deck. Not all patents are created equal, however, and a patent is only as valuable as the exclusivity its claims confer. The more consequential inquiry, and the one that separates rigorous diligence from a checklist exercise, is what those patents actually claim.
Intellectual property diligence should feature an evaluation of the overall quality of a company’s patent portfolio, with particular attention to how the claims match a life sciences company’s product or trajectory. Investors engaging in diligence should consider not only whether a company has filed applications or has issued patents, but whether the patent portfolio includes claims representative of the core asset, and with meaningful scope to preclude competition. Depending on the stage of the company, “meaningful scope” could refer to pending claims with optionality to cover the most important drug products as they develop or issued claims that cover the clinic-ready form of the drug.
Two distinct attributes are embedded in that inquiry, and a portfolio can satisfy one while failing the other. The first is whether the claims accurately capture the core asset as it is developing. The second is whether the claims are broad enough to keep competitors out. Claims can precisely describe a company’s lead molecule and still be so narrow that a competitor designs around them with modest effort. Conversely, claims can be impressively broad and yet not cover the form of the product that will ultimately reach the clinic. The sections that follow address each attribute in turn, examine the breadth-versus-support tension that constrains both, and then situate the analysis within a portfolio-wide view.
Research and Development as a Moving Target
As a company develops from an early-stage company with promising assets to a mature, pipeline-focused company, the intellectual property portfolio should evolve similarly. However, it is not uncommon that an R&D program can branch out or evolve out of pace with the patent strategy. An investor should consider how all variables surrounding the drug are covered or will be covered by claim strategy, whether a company is building its first preclinical proof of concept package, preparing to launch a Phase I trial, or preparing for large-scale clinical studies.
The risk is easy to underappreciate because it develops quietly. A molecule that looked like the lead candidate at Series A may be superseded by a backup, a reformulation, or a next-generation construct by the time the company reaches the clinic, and the claim strategy does not always keep pace. When the protected molecule and the developed molecule diverge, a portfolio that once looked strong can end up covering the wrong asset. An investor should therefore evaluate not just what the claims cover today, but whether the prosecution strategy is positioned to follow the program as it moves.
An intellectual property portfolio’s growth pattern can vary depending on whether the company’s foundational strategy is built off a platform or a single asset. Platform companies may engage in exploratory R&D, filing new applications around the same core technology. When performing due diligence on a platform company, an investor should evaluate whether the most tractable asset is explicitly covered in the portfolio. Asset-focused companies that are headed quickly toward the clinic may be rapidly optimizing developability, formulation, and dosing of the drug substance. As the company matures, it is also very likely that indication prioritization will evolve. Accordingly, the company should have a patent portfolio that proactively covers these areas of evolution.
The mechanism that keeps a portfolio aligned with a moving program is a well-managed continuation practice. Companies that keep at least one application pending in each key family retain the ability to draft new claims against a competitor’s product, a newly optimized lead, or an unanticipated formulation as the science clarifies. An investor should look for that pendency as a marker of forward-looking strategy and should treat a family in which every application has issued or gone abandoned, with no continuation on file, as a meaningful limitation on future optionality, particularly for an early-stage company whose product definition is still in flux. The most important question in proactive claim diligence is not only whether today’s claims are adequate, but whether the company has preserved the procedural runway to adapt them.
Claim Scope and the Competition Problem
Investors should also consider whether the product is sufficiently covered by pending or issued claims to preclude competition. Even if the asset itself is accurately covered by the claims, narrow claims focused on the precise embodiment of the product (for example, the exact sequence of a novel, full-length antibody) may have limited economic value. Sophisticated research teams working in well-established modalities like antibodies or small molecules, particularly with the help of AI tools, can draw upon tens of thousands of drug candidates for a single target or epitope. This can create significant competition around a disclosed target and reduce market share for companies with narrow intellectual property protection.
The strategic implication is that disclosing a target without adequately claiming around it can be actively harmful. Once a competitor understands which target or epitope a company is pursuing, it can often engineer a differentiated molecule that achieves the same biology while falling outside narrowly drafted claims. Narrow protection, in other words, can invite the very competition that patents are meant to foreclose. This is why claim scope, and not merely claim accuracy, belongs at the center of the analysis.
What adequate breadth looks like is modality-dependent, and a sophisticated diligence exercise should ask whether the portfolio reaches beyond the single disclosed embodiment in the ways available to that class of asset. For an antibody, breadth may refer to claims that are defined by the complementarity-determining regions and by the therapeutic method of use, rather than by the full-length sequence alone. For a small molecule, breadth may refer to genus claims covering a Markush structure, salt and polymorph forms, and key metabolites, in addition to the specific compound advancing toward the clinic. An investor should not expect an investment target to hold every feasible category of claim to cover the product. Instead, the investor should focus on ensuring that the company has pursued the types of claims that carry real, exclusionary weight.
Claim scope should be a stage-specific evaluation process. Seed-stage or pre-IND companies should have filed applications with both broad and narrow claims, including “picture claims” that tightly encompass the drug product. This allows for “fall-back” positions during prosecution, allowing a company to start with a broad claim and progressively narrow as needed for allowance. For Series B or clinical-stage companies, investors should expect some issued claims with scope that both covers the most important drug product and meaningfully protects against competition.
The Breadth–Support Trade-Off
Investors should consider enablement pitfalls for companies that have overly broad pending or issued claims. For claims in prosecution, investors should expect very broad claims to be narrowed to the specific embodiments recited in the application, that is, the sequences and structures for which the company has shown proof of concept in the patent application. Conversely, investors should consider the relative strength or weakness of issued claims with broad scope. A patent with broad claims and limited disclosed embodiments may not stand up well in litigation, where written description and enablement under 35 U.S.C. § 112 are common grounds of attack. Thus, an investor and their counsel should incorporate into claim diligence an understanding of how the claims compare to the subject matter disclosed in the application. Likewise, companies that are actively filing applications should be sure to be comprehensive, capturing not only the lead embodiment but the reasonable extent of competitive alternatives.
This tension has particular implications for biologics and other functionally claimed genus inventions. A claim defined by a desired function (for example, a claim to all antibodies that bind a particular antigen and block its activity) can be especially vulnerable if the specification includes only a few examples with experimental data and leaves the rest of the claimed space to trial and error. Courts have grown increasingly demanding about the validity of such broad functional claims, and a genus claim that is not commensurate with what the specification teaches can be invalidated even after issuance. For investors, the practical consequence is that an impressively broad issued claim is not self-authenticating. Its durability depends on whether the disclosure describes and enables enough of the claimed genus to survive a challenge, and that assessment belongs in diligence rather than being deferred to the first litigation.
The practical takeaway is that breadth and support must be assessed together. The right question is not simply how broad the claims are, but how broad they are relative to what the specification can defend. Claims that outrun their disclosure invite narrowing in prosecution and vulnerability in litigation; claims that are well supported but drawn too tightly may issue cleanly and still fail to exclude competitors. The most valuable positions are those in which meaningful breadth is matched by a disclosure robust enough to sustain it. And a company that has invested in generating the underlying data to support broad claims has usually built a more defensible asset than one that has simply drafted aggressively.
The Portfolio Perspective
Finally, for all investors, particularly those that invest in late-stage private companies, make crossover investments, or participate in public investments, a portfolio-wide perspective is essential. A mature company whose core product is covered by older composition patents should have developed a life-cycle management strategy to extend protection. Where applicable, this could include pursuing methods of treatment or methods of manufacturing, as well as formulation and dosing patents that layer additional exclusivity on top of the original composition coverage. The investor’s task is to determine whether the portfolio, taken as a whole, sustains a durable exclusivity runway – not merely whether any one patent looks strong in isolation.
A portfolio-wide view also means reading claim quality alongside the other levers that determine the exclusivity runway. The most robust composition claim contributes little if it expires before or shortly after approval, so the analysis should map key claims against the projected development timeline and against the patent term extension and regulatory exclusivity the asset can expect to receive. A later-filed method-of-treatment or formulation patent with strong, well-supported claims may ultimately carry more commercial weight than an aging composition patent, because it protects the product further into its commercial life. Claim quality, in other words, is not assessed patent by patent in isolation but as the load-bearing element of an exclusivity strategy that unfolds over time.
Conclusion
Claim quality and scope are driven by the same discipline that generally underlies rigorous IP diligence: a willingness to look past the mere existence of a patent to the substance of what it protects. The decisive questions are (1) whether the claims track the asset as it is actually developing, (2) whether the company has preserved the prosecution optionality to keep pace, (3) whether the claims are broad enough to keep a well-resourced competitor from engineering around them, (4) whether their breadth is matched by disclosure that will hold up under challenge, and (5) whether the portfolio as a whole builds an exclusivity runway long enough to justify the capital to be deployed. Investors who evaluate claims with this level of nuance and specificity will more reliably distinguish assets that are genuinely insulated from competition from those that merely appear to be.
Part 1 — Clearing the Path: How Freedom-To-Operate Analysis Should Drive Life Sciences Investment Decisions